538 results about "Non alcoholic" patented technology

The present invention relates to characterizing changes in mammalian gastrointestinal microbiota associated with antibiotic treatment and various disease conditions (such as obesity, metabolic syndrome, insulin-deficiency or insulin-resistance related disorders, glucose intolerance, diabetes, non-alcoholic fatty liver, abnormal lipid metabolism, short stature, osteoporosis, and other disorders of bone formation and mineralization, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of probiotics, prebiotics, or narrow spectrum antibiotics / anti-bacterial agents that are capable of restoring healthy mammalian bacterial gastrointestinal microbiota.

A highly safe and effective prophylactic / ameliorating or therapeutic agent for NACH and the method for using the same are provided.A prophylactic / ameliorating or therapeutic agent for NASH containing a combination of at least one first ingredient selected from the group consisting of an ω3PUFA and pharmaceutically acceptable salts and esters thereof and at least one second ingredient selected from the group consisting of (a) a biguanide hypoglycemic agent, (b) a nonsteroidal anti-inflammatory drug, (c) a 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitor, and (d) an angiotensin II receptor blocker as the active ingredients; and its method of use.

The disclosure provides for a method for treating a fatty liver disorder in a subject in need thereof, comprising selecting a subject having or suspected of having a fatty liver disease or disorder, wherein the subject is non diabetic, pre-diabetic, mildly diabetic, or has normal or substantially normal biliary tract function; and administering a therapeutically effective amount of a pharmaceutical composition comprising ethyl eicosapentanoate (EPA-E). In some cases EPA-E present may be at least 40% by weight in total of the fatty acids and their derivatives.

The invention relates generally to compositions comprising antioxidants useful for reducing oxidative stress and lipid peroxidation, and treating chronic liver disease, chronic hepatitis C virus infection and non-alcoholic steatohepatitis. In particular, the invention relates to the preparation and oral administration of compositions comprising glycyrrhizin, schisandra, ascorbic acid, L-glutathione, silymarin, lipoic acid, and d-alpha-tocopherol. The invention also relates to the preparation and parenteral administration of compositions comprising glycyrrhizin, ascorbic acid, L-glutathione, and vitamin B-complex, preferably by infusion or intravenous injection. The invention further relates to methods of using the antioxidants, oral compositions and parenteral compositions.

The object of the present invention is to minimize the risks of dose dumping associated with the concomitant consumption of alcohol and certain modified-release pharmaceutical or dietetic forms. The invention relates to an oral form comprising microparticles of the reservoir type for the modified release of at least one active principle (AP), characterized in that it is resistant to immediate dumping of the dose of AP in the presence of alcohol. In particular, the oral form according to the invention is characterized in that the time taken to release 50% of the AP in an alcoholic solution is not reduced more than 3-fold relative to the time taken to release 50% of the AP in an alcohol-free aqueous medium. The form comprises an agent D, which is a pharmaceutically acceptable compound whose hydration or solvation rate or capacity is greater in an alcohol-free aqueous medium than in alcoholic solution

The present invention relates to production of non-alcoholic beverage enriched with 1H216O in comparison with typical non-alcoholic beverage composition. This is provided by addition to alcoholic beverage highly pure light water comprising 1H216O from about 99.76% to about 99.99% by weight of water, while the content of 1H216O in typical water is no more than 99.575 by weight of water. According to the present invention non-alcoholic beverage enriched with 1H216O in an amount no less than 99.76% by weight of water, includes drinking water, table drinking water, mineralized water, mineral water, mineral table water, treatment-prophylactic mineral water, mineral-medicinal water; blended beverage which is table beverage, beverage for special purposes, refreshing beverage, cool beverage, tonic, lemonade, non-alcoholic cocktail; and beverage which is juice, nectar, kissel, mors, tea, kvass, non-alcoholic beer. The taking non-alcoholic beverages enriched with 1H216O, wherein the content of 1H216O is no less than 99.76% by weight of water of said non-alcoholic beverage prepared in accordance with present invention improves human wellness and life quality.

The object of the present invention is to provide PPAR (peroxisome proliferator-activated receptor) activity regulators, which can be widely used for improving insulin resistance and preventing / treating various diseases such as diabetes, metabolic syndromes, hyperlipemia, high-blood pressure, vascular disorders, inflammation, hepatitis, fatty liver, liver fibrosis, NASH (non-alcoholic steatohepatitis) and obesity.The present invention provides PPAR activity regulators which comprise an acylamide compound having the specific structure, prodrugs thereof, or pharmaceutically acceptable salts thereof.

The skin formulation is a non-alcoholic composition for treating and alleviating skin disorders, including dermatitis, rough skin, cracking, itching and psoriasis. The formulation includes only natural ingredients. All oils in the formulation are unadulterated or minimally processed and do not result in irritation to the skin or other harmful side effects. The compositions can be formulated as a lotion, lotion bar, or a soap.

The invention provides a composition of matter for treating infected skin and mucousal membranes, said composition comprising at least one anti-microbial drug; and at least one essential oil, in combination with a substantially, alcohol-free carrier system, said carrier being selected from a liquid carrier or a semi-solid carrier, said carrier system being selected from isotonic system and a moderately hypertonic system.

The invention relates to the discovery that farnesoid X receptor (FXR) agonists can be used in combination with peroxisome proliferation activated receptor gamma (PPARγ) agonists to reduce drug-induced adverse side effects in patients suffering from conditions such as insulin resistance, Type II diabetes, metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and heart disease. Particularly, the present invention encompasses methods for treating patients suffering from drug-induced adverse side effects with selective PPARγ, dual PPARα / γ and pan PPARα / γ / δ agonists in combination with FXR agonists.

The present invention provides methods of treating TNF-α-mediated disorders, the methods generally involving administering to an individual in need thereof effective amounts of pirfenidone or a pirfenidone analog and a second therapeutic agent that reduces TNF-α synthesis or that reduces TNF-α binding to a TNF receptor. The present invention further provides methods for treating non-alcoholic steatohepatitis, the method generally involving administering to an individual in need thereof an effective amount of pirfenidone. The present invention further provides methods of treating end-stage or advanced Type II diabetes, the methods generally involving administering to an individual in need thereof effective amounts of pirfenidone and insulin.

Disclosed is a novel NASH marker for use in a method for detecting NASH or evaluating the severity of NASH, which utilizes at least one factor selected from the group consisting of an IL-1 receptor antagonist, sCD40, HMGB1, sPLA2 group IIA and an sPLA2 activity as the marker. Also disclosed is a method for detecting NASH or evaluating the severity of NASH in a subject, which utilizes the marker.

The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and / or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and / or high triglycerides and / or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided.

The invention relates to a preparation method of high purity bulleyaconitine A. The preparation method comprises the following steps: root of radix aconiti feri of Yunnan is crushed, and acid alcoholic solvent or alcohol water solution is used for diacolation, and supersound or thermal refluxing extraction. The extracting solution is decompressed and concentrated to be non-alcoholic at the temperature of 80 to 90 DEG C, cooled down to room temperature, to ensure the relative density to be 1.00 to 1.30; standing is performed for 10 to 20 hours; the extracting solution is filtered; the pH is adjusted to 6.0 to 8.0 with basifier; and then the extracting solution is extracted with ethyl acetate or chloroform. The ethyl acetate or chloroform liquid is contracted, column chromatography is performed to the obtained paste, silica gel or neutral alumina are used as fillers, any one of solvent vapor-acetone-diethylamine, ligarine-acetone-diethylamine or cyclohexane-acetone-diethylamine is used for eluation, the bulleyaconitine A in the collected liquid is constantly checked during the thin layer chromatography, the collected liquid containing the bulleyaconitine A is merged, the solvent is concentrated, carbinol or ethanol is dissolved, filtering is performed, crystallization is performed at room temperature, filtering is performed, the crystal is repeatedly rinsed with carbinol or ethanol, and the final product is obtained. The purity of the obtained product is high, the production cost is low, and the toxicity of the used organic solvent is low.

The invention provides oat composite nutrition slurry and a preparation method thereof, which relates to a non-alcoholic drink. The raw material comprises oat, sesame, soya, brown rice, buckwheat, wheat germ, white granulated sugar, liquid native starch anti-aging agent and composite phosphate. The oat, the sesame, the soya, germinate brown rice, the buckwheat and the wheat germ are roasted; the roasted oat, soya, germinate brown rice, buckwheat and wheat germ are crushed and compounded into paste by adding water to prepare slurry A; the roasted sesame and wheat germ are grinded so as to obtain sesame wheat germ flour; the liquid native starch anti-aging agent is uniformly mixed with the white granulated sugar where hot water is added so as to obtain the liquid native starch anti-aging agent solution; the composite phosphate is dissolved by water so as to gain the composite phosphate solution; the slurry A is mixed with the sesame wheat germ flour where the liquid native starch anti-aging agent solution and the composite phosphate solution are added so as to obtain slurry B; the white granulated sugar is dissolved into syrup C by water; the slurry B and the syrup C are added with water for constant volume so as to obtain compounding solution; and the steps as follows are carried out to prepare the oat composite nutrition slurry: cooling, pre-heating, degassing, homogenizing, sterilizing, filling and packaging.

Disclosed is a method and composition for nutritional compositions containing -glucosidase inhibitors, and more specifically Touchi Extract and its uses in the treatment of many disorders. These disorders include diabetes, hyperlipidemia, obesity, Metabolic syndrome / Syndrome X, COPD, malabsorption, Crohn's disease, diarrhea, constipation, irritable bowel syndrome, human immunodeficiency virus, cystic fibrosis, non-alcoholic steatohepatitis, polycystic ovarian syndrome including associate infertility, and erectile dysfunction. Further, -glucosidase inhibitors, and more specifically Touchi Extract can be used to aid healing in critical care patients and for general wound healing. Additionally, -glucosidase inhibitors, including Touchi Extract can be used to enhance athletic performance.

The present invention is drawn to a new diagnosis method for detecting the extent of alcoholic or non-alcoholic steato-hepatitis in a patient, in particular in a patient suffering from a disease involving alcoholic or non-alcoholic steato-hepatitis or who already had a positive diagnosis test of liver fibrosis and / or presence of liver necroinflammatory lesions, by using the serum concentration of easily detectable biological markers. The invention is also drawn to diagnosis kits for the implementation of the method.

A method for reducing the likelihood of developing non-alcoholic steatohepatitis (NASH) in an individual diagnosed with non-alcoholic fatty liver disease involves providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species, and at least 6 grams per day of fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual. In certain embodiments, monoacylglycerolacyltransferase-3 (MGAT3) synthesis is inhibited to lower triacylglycerol (TAG) production, while in others, expression of diacylglycerolacyltransferase-2 (DGAT-2) is inhibited. The beneficial bacteria are preferably modified to produce increased amounts of butyrate and are also encapsulated in a frangible enclosure. Levels of Roseburia are preferably increased while the levels of Akkermansia spp. in the individual's gut microbiome are reduced.

The invention provides relates to the technical field of production of crystalline silicon solar batteries, in particular to a non-alcoholic monocrystalline silicon flock making additive. The non-alcoholic monocrystalline silicon flock making additive consists of citric acid (sodium citrate), sodium dodecyl benzene sulfonate and deionized water. When the non-alcoholic monocrystalline silicon flock making additive is applied to manufacturing of suede of a monocrystalline wafer, uniform, thin and dense suede pyramid can be obtained without using alcohol such as isopropanol or ethanol, so the flock manufacturing cost can be reduced, environmental pollution caused by the alcohol is avoided, the process of the crystalline silicon solar battery is stable, and good practical value is achieved.

A method is provided for substantially instantaneously wetting hydrophobic, porous polymeric membranes and for rendering hydrophobic membranes hydrophilic. The method involves treating the membrane with a non-alcoholic aqueous solution of a low molecular weight surfactant, and then drying the treated membrane. The low molecular weight surfactant exhibits high polymer affinity for the hydrophobic membrane substrate as well as high water solubility; a preferred surfactant is sodium dodecylbenzenesulfonate (SDBS). The method is particularly useful for treating hydrophobic membranes such as those made of polyolefins, fluorinated or chlorinated polymers, polysulfone, or polyethersulfone, preferably having a pore size of about 0.01 microns to about 1 micron. A wettable membrane is thus provided as the aqueous surfactant solution is absorbed into the hydrophobic membrane.

The present invention provides methods of treating a subject with non-alcoholic fatty liver disease (NAFLD), insulin resistance, obesity or hyperlipidemia, comprising administering to the subject an effective amount of a compound according to Formula I:or a physiologically acceptable salt thereof.

An aqueous, heat and cold stable, non-alcoholic or slightly-alcoholic microemulsion based antimicrobial mouthwash composition with improved antimicrobial efficacy. The composition comprises a unique water-soluble matrix composite, at least one water-immiscible or water-insoluble antimicrobial agent, and optionally, a preservative or preservative system, a weak carboxylic acid, a coloring agent and other additives. Examples of antimicrobial agents include menthol, thymol, eucalyptol and / or methyl salicylate. A process for preparing the oral care composition is also disclosed.

Methods useful for reducing or preventing non-alcoholic steatohepatitis or hepatic steatosis are provided herein. Such methods may comprise administering to a subject in need thereof a sirtuin pathway activator and / or PDE5 inhibitor alone or in combination with an amount of a branched amino acid in free amino acid form, or a metabolite thereof. Also provided herein are compositions and kits for practicing any of the methods described herein.

The present invention discloses an application of pentacyclic triterpenoid saponin represented by formulas (I) to (XIII) for the preparation of a medicine for preventing or treating AMPK-mediated diseases including fatty liver disease, inflammatory bowel disease, respiratory disease, diabetic complications and polycystic kidney disease. The compounds of formula (I) to (XIII) are especially usefulfor nonalcoholic simple fatty liver, nonalcoholic steatohepatitis, non-alcoholic steatohepatitis-induced cirrhosis, ulcerative colitis, Crohn's disease, chronic obstructive Pulmonary diseases, asthma,idiopathic pulmonary fibrosis, cystic fibrosis, allergic rhinitis, diabetic nephropathy, diabetic cardiomyopathy, diabetic ulcers, and autosomal dominant polycystic kidney disease. A pharmaceutical composition for preventing and treating the AMPK-mediated diseases of the present invention comprises a therapeutically effective amount of the compounds of the formula (I) to (XIII) or a pharmaceutically acceptable salt or a solvate thereof as an active ingredient and a pharmaceutically acceptable excipient.